Xellia’s new pharmaceutical laboratory delivered in Budapest

As Xellia’s centre of excellence, the laboratory will operate as a testing centre for active ingredients produced by all units

The latest development by the Danish pharmaceutical company Xellia Pharmaceuticals has been completed at its Kőbánya site, Budapest. As Xellia's centre of excellence, the laboratory constructed as part of a development of EUR 11 million will operate as a testing centre for active ingredients produced by all units and so it will play an important role in the global operating strategy of the Danish pharmaceutical company. As a result of the expansion, more than 40 new jobs have been created so far, and through the ongoing hiring process Xellia would increase the size of the team participating in the operation of centralised laboratory services to 80 in 2019.

Péter Szijjártó, Minister of Foreign Affairs and Trade

With its more than 100 years of experience, the Copenhagen-based Xellia Pharmaceuticals which specialises in the production of pharmaceutical products for the treatment of serious and life-threatening infections is a leading developer, manufacturer and supplier in the pharmaceutical industry. In more than 70 countries, the company has relations with approximately 500 partners in the healthcare sector. At present, the company employs nearly 1,200 people in its operation and production units located in Denmark, Hungary, the United States and China.

The new facility with a floor area of about 3,000 square-metres was constructed next to Xellia's plant manufacturing active pharmaceutical ingredients, which currently employs a staff of 200. All Xellia medicines produced worldwide will undergo final checking and testing in the laboratory complex, where state-of-the-art microbiological and chemical analytical laboratories have been established. Hungarian engineers, pharmacists and microbiologists will give the final approval for placing Xellia pharmaceutical products on the market.

Péter Szijjártó, Carl-Ake Carlsson, CEO of Xellia Pharmacauticals and Zsolt Németh, Managing director of Xellia's Hungarian subsidiaries

In his address, Xellia Pharmaceuticals CEO Carl-Ake Carlsson emphasised: the company is committed to high quality work and making excellent products, which is guaranteed by the competence of the Hungarian employees. According to him, the company's management is also considering the establishment of additional R&D activities in Hungary.